Some studies have suggested that BPC-157 sensitizes growth hormone receptors enhancing their responsiveness to circulating growth hormone without directly elevating GH levels
No peptide in this category is approved by the FDA, EMA, or ANSM for therapeutic use in tissue repair
Serious neuropsychiatric and neurological problems can develop, if left untreated
Because pernicious anemia is often autoimmune, complete prevention is not always possible
The Company has 8,396,600 warrants outstanding from prior financings EMCs Position in the Company Emerging Markets Consulting participated directly in this financing by investing: CAD $671,356 Purchasing: 1,342,712 shares at CAD $0.50 per share, representing approximately 33.6% of the CAD $2,000,000 offering (Note: $671,356 of a $2,000,000 round is 33.6%.) In addition, we separately acquired: 1,000,000 additional shares through a private transaction EMCs total holding of 2,342,712 shares represents approximately 4.47% of the 52,431,207 common shares outstanding